SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Fuel Tech, Inc. (Nasdaq: FTEK) $6.53.Today announced receipt of air pollution control (APC) orders totaling $5.6 million. The largest of these orders, placed by a major domestic power producer, represent nitrogen oxide (NOx) reduction projects on two coal-fired boilers. These projects, on medium-sized units, will utilize Fuel Tech’s HERT High Energy Reagent Technology™ and NOxOUT Selective Non-Catalytic Reduction (SNCR) injection technologies. Equipment deliveries are scheduled for the third quarter of 2011. These orders are part of a larger alliance agreement which calls for the potential supply of SNCR systems and related services for multiple coal-fired generating units.
Additionally, an order was received for two ULTRA systems on two 330MW coal-fired units from an existing customer in a single power generation site in northeast China. The systems will provide ammonia as a reagent in support of units outfitted with selective catalytic reduction (SCR) systems for NOx control. Equipment deliveries are scheduled for the first quarter of 2011.
What They Do: Fuel Tech is a leading technology company engaged in the worldwide development, commercialization and application of state-of-the-art proprietary technologies for air pollution control, process optimization, and advanced engineering services.
Ardea Biosciences (Nasdaq: RDEA) $24.46. Today announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric) and allopurinol. RDEA594, Ardea's lead product candidate for the chronic management of hyperuricemia and gout, is an orally administered compound that inhibits the URAT1 transporter, a biological mechanism that is different from, but complementary to, that of allopurinol and febuxostat. While allopurinol and febuxostat account for greater than ninety percent of U.S. prescriptions for the chronic treatment of gout, approximately one half of patients do not adequately respond to standard doses of these drugs, leaving a significant portion of the gout population with limited options.
What They Do: Ardea Biosciences is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases.
ShengdaTech (Nasdaq: SDTH) $6.32. Today announced its unaudited financial results for the three months and nine months ended September 30, 2010. Net sales from continuing operations in the third quarter of 2010 increased by 35.6% to $34.4 million from $25.4 million in the third quarter of 2009. The net sales increase was largely due to higher sales volume as a result of the Company's expanded production capacity, improved capacity utilization to meet the growing market demand, as well as an increase in average selling price.
Net income from continuing operations in the third quarter of 2010 increased 45.3% to $7.0 million compared with $4.8 million in the same period last year. Fully diluted earnings per share from continuing operations for the third quarter of 2010 were $0.13, compared with fully diluted earnings from continuing operations per share of $0.09 in the same quarter of 2009.
Fully diluted weighted-average shares outstanding were 54,205,865 in the third quarter of 2010, down from 54,207,742 in the same quarter last year. The number of potential common shares associated with the Company's convertible debt were anti-dilutive during both periods and therefore were excluded from the diluted earnings per share computation.
EBITDA was $13.2 million in the third quarter of 2010, up 40.4% from $9.4 million in the same quarter of 2009.
What They Do: ShengdaTech is engaged in the business of manufacturing, marketing, and selling nano-precipitated calcium carbonate (NPCC) products
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
